Glenmark Pharmaceuticals enterprise value

·Pharma & HealthChart ›
MultiplesEnterprise valuePer share
Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
64,906————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
1,1751,1751,6761,6581,443
−0.3−0.3−0.4−0.4365
0.00.02,1949914,348
63,731————
−1,175−1,175518−6682,905
₹2,258.36————
10,51210,51211,0438,83814,187
0.0%0.0%19.9%11.2%30.6%
3.59×————
13.29×————
15.25×————
30.53×————
Reference items — trailing FY values
17,73716,98313,32211,81312,990
4,7974,5722,3511,1952,278
4,1803,9991,8656131,667
—3,445−828−265625
2,0872,087−1,577−1,16417.6
—2,029−1,625−1,474−159
—1,358750898608
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

GLENMARK₹2,300.00

Glenmark Pharmaceuticals Ltd.

· Pharma & Health
₹ CrorePeersDRREDDYLUPINALKEMBIOCONMANKINDLAURUSLABSFORTISAUROPHARMAMcap ₹64,906 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization————64,906.0
- Cash, Equiv & ST Investments1,443.01,658.31,675.71,174.71,174.7
+ Minority Interest365.3-0.4-0.4-0.3-0.3
+ Total Debt4,347.7990.62,194.20.00.0
Enterprise Value————63,731.0
Net Debt (memo)2,904.7-667.7518.5-1,174.7-1,174.7
EV per Share————2,258.36
Total Capital14,187.08,838.111,043.310,511.810,511.8
Total Debt/Total Capital30.6511.2119.870.000.00
EV/Sales————3.59
EV/EBITDA————13.29
EV/EBIT————15.25
EV/Free Cash Flow————30.53
Reference Items — Trailing FY Values
Sales12,990.111,813.113,321.716,982.517,736.6
EBITDA2,278.41,195.32,351.44,572.44,796.7
EBIT1,667.1613.41,865.43,998.94,180.0
Operating Cash Flow625.4-265.4-827.63,445.0—
Free Cash Flow17.6-1,163.8-1,577.22,087.32,087.3
FCFF (free cash flow to the firm)-158.5-1,473.9-1,625.22,028.5—
Capital Expenditure607.8898.4749.61,357.7—
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.